Sangart, Inc. Completes Patient Enrollment in Phase 2B Clinical Trial of MP4OX in Traumatic Hemorrhagic Shock Patients
10/9/2012 7:36:06 AM
More...
|
Sangart, Inc. Grabs $50 Million Series G Funding
5/25/2012 6:42:13 AM
More...
|
Sangart, Inc. Enhances Leadership Team Bringing Superior Depth of Expertise
2/15/2012 9:26:26 AM
More...
|
Sangart, Inc. Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
1/13/2012 10:04:35 AM
More...
|
Sangart, Inc. Plans Extra Hiring at Irish Plant
8/23/2011 7:20:20 AM
More...
|
Pharma Firm Sangart, Inc. to Create 245 Jobs in Ireland
7/21/2011 8:14:43 AM
More...
|
Sangart, Inc. Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
6/14/2011 8:51:14 AM
More...
|
Sangart, Inc. Announces Closing of $50 Million Series G Financing
4/20/2011 7:04:08 AM
More...
|
Sangart, Inc. Announces Cooperative Research and Development Agreement With the U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury
12/6/2010 8:58:17 AM
More...
|
Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
11/15/2010 10:18:15 AM
More...
|
|